225 related articles for article (PubMed ID: 19917377)
1. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Zhu X; Chen J; Han F; Cheng M; Xu L; Zhang L; Ding X; Le Y
Transplant Proc; 2009 Nov; 41(9):3736-42. PubMed ID: 19917377
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
Nouri-Majalan N; Ghafari A; Moghaddasi S
Transplant Proc; 2009 Sep; 41(7):2832-4. PubMed ID: 19765449
[TBL] [Abstract][Full Text] [Related]
3. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
4. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Wang AY; Yu AW; Lam CW; Yu LM; Li PK; Goh J; Lui SF
Am J Kidney Dis; 2002 Mar; 39(3):600-8. PubMed ID: 11877580
[TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells.
Lezaic V; Biljanovic-Paunovic L; Pavlovic-Kentera V; Djukanovic L
Eur J Med Res; 2001 Jan; 6(1):27-32. PubMed ID: 11313188
[TBL] [Abstract][Full Text] [Related]
6. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.
Kessler M; Hestin D; Mayeux D; Mertes PM; Renoult E
Clin Nephrol; 1996 Feb; 45(2):83-9. PubMed ID: 8846535
[TBL] [Abstract][Full Text] [Related]
7. Factors inducing posttransplant erythrocytosis.
Lezaić V; Djukanović LJ; Pavlović-Kentera V; Clemons G; Biljanović-Paunović L
Eur J Med Res; 1997 Sep; 2(9):407-12. PubMed ID: 9300939
[TBL] [Abstract][Full Text] [Related]
8. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients.
Karbowska A; Boratynska M; Kusztal M; Klinger M
Transplant Proc; 2009 Oct; 41(8):3052-5. PubMed ID: 19857674
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricemia influences chronic cyclosporine nephropathy.
Saglam F; Celik A; Sarioglu S; Cavdar C; Sifil A; Gulay H; Camsari T
Transplant Proc; 2008; 40(1):167-70. PubMed ID: 18261576
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of Cordyceps sinensis on immunosuppressive therapy in renal transplantation.
Li Y; Xue WJ; Tian PX; Ding XM; Yan H; Pan XM; Feng XS
Transplant Proc; 2009 Jun; 41(5):1565-9. PubMed ID: 19545680
[TBL] [Abstract][Full Text] [Related]
11. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
[TBL] [Abstract][Full Text] [Related]
12. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
Ersoy A; Kahvecioglu S; Ersoy C; Cift A; Dilek K
Transplant Proc; 2005 Jun; 37(5):2148-50. PubMed ID: 15964363
[TBL] [Abstract][Full Text] [Related]
13. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
Tumgor G; Arikan C; Kilic M; Aydogdu S
Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study.
Naritomi H; Fujita T; Ito S; Ogihara T; Shimada K; Shimamoto K; Tanaka H; Yoshiike N
Hypertens Res; 2008 Feb; 31(2):295-304. PubMed ID: 18360050
[TBL] [Abstract][Full Text] [Related]
15. Effects of losartan on the treatment of posttransplant erythrocytosis.
Navarro JF; García J; Macía M; Mora C; Chahin J; Gallego E; Méndez ML; del Castillo N
Clin Nephrol; 1998 Jun; 49(6):370-2. PubMed ID: 9696433
[TBL] [Abstract][Full Text] [Related]
16. [Incidence and management of anemia in renal transplantation: an observational-French study].
Choukroun G; Deray G; Glotz D; Lebranchu Y; Dussol B; Bourbigot B; Lefrançois N; Cassuto-Viguier E; Toupance O; Hacen C; Lang P; Mazouz H; Martinez F
Nephrol Ther; 2008 Dec; 4(7):575-83. PubMed ID: 18672417
[TBL] [Abstract][Full Text] [Related]
17. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy.
Akalin E; Ganeshan SV; Winston J; Muntner P
Transplantation; 2008 Sep; 86(5):652-8. PubMed ID: 18791445
[TBL] [Abstract][Full Text] [Related]
18. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
Stigant CE; Cohen J; Vivera M; Zaltzman JS
Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
[TBL] [Abstract][Full Text] [Related]
19. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
Iseki K; Ikemiya Y; Inoue T; Iseki C; Kinjo K; Takishita S
Am J Kidney Dis; 2004 Oct; 44(4):642-50. PubMed ID: 15384015
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients.
Nart A; Sipahi S; Aykas A; Uslu A; Hoşcoşkun C; Toz H
Transplant Proc; 2008; 40(1):189-92. PubMed ID: 18261583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
